The Servier FAST Discovery Award recognizes the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology and neuroscience, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.
Servier is looking for startups developing innovative approaches in the following discovery and early clinical areas of interest:
Innovative therapeutic approaches in:
– Oncology: Cancer cell targeting (e.g., synthetic lethality, precision oncology)
– Neurology: Rare neurological disorders (e.g., familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
AI/ML data-driven platforms for drug design (including small molecules, oligonucleotides and antibodies) and to support translational activities (target and biomarker identification).
Your non-confidential application should highlight your innovative approach to advancing therapies for patients with high unmet needs. All submissions will be reviewed by Servier, and one awardee will be selected to receive the Servier FAST Discovery Award, a fast-tracked spot in the Fall 2025 FAST California program. Learn more about FAST California here.
Timeline:
Disclosures:
The winner of the Servier FAST Discovery Award will be fast-tracked into the Fall FAST 2025 program cohort. A dedicated advisor from Servier will participate as an advisor to that selected company and participate in the awardees advisory meetings.
Any questions or comments can be directed to Shikha Sharma at [email protected].
Servier, a global leader in oncology governed by a non-profit foundation, approaches innovation with a long-term vision, free of influence from fiduciary responsibilities.
Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Neurology is also a key research focus area for the company, one their team is actively building out through collaborations, partnerships and internal research. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.
Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.
For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.us.